Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.80 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.80 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7316123 | 1.00 | CRBN (0.80) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL21238836 | 1.00 | CRBN (0.80) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL7327043 | 1.00 | CRBN (0.80) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL21238842 | 1.00 | CRBN (0.80) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL1833732 | 0.98 | CRBN (0.76) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL21238727 | 0.97 | CRBN (0.84) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL21238913 | 0.95 | OR51E2 (0.75) | CRBNFKBP5OR51E2KDM4EGAA | |
| Piperidine SCHEMBL9851948 | 0.95 | OR51E2 (0.75) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL21238909 | 0.95 | OR51E2 (0.75) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL21238907 | 0.95 | OR51E2 (0.75) | CRBNFKBP5OR51E2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160357901-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | BURGESS KEVIN (US) | 2016-12-08 | — | — | US | disclosed |
| US-20130288331-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | BURGESS KEVIN (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2001045707-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130288331-A1 | PEPTIDOMIMETIC COMPOUNDS AND RELATED METHODS | SERBP1, PAIP1, DNPEP | CRBN 1966/4885FKBP5 460/4885OR51E2 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.